Moderators:

• Wendy Brewster, MD, PhD, University of North Carolina School of Medicine,
  Chapel Hill, NC
• S. Diane Yamada, MD, University Of Chicago, Chicago, IL

Location: Kamehameha 3

Late-breaking Abstracts

• LBA#1: Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
  E.Pujade-Lauraine1, K.Fujiwara2, J.A.Ledermann3, A.M.Oza4, R.S.Kristeleit3, I.L.Ray-Coquard5, G.E.Richardson6, C.Sessa7, K.Yonemori8, S.Banerjee9, A.Leary10, A.V.Tinker11, K.H.Jung12, R.Madry13, S.Y.Park14, C.K.Anderson15, F.Zohren16, R.Stewart17, C.Wei18, S.S.Dychter17 and B.J.Monk19
  1ARCAGY-GINECO, Paris, France, 2Saitama Medical University International Medical Center, Hidaka, Japan, 3UCL Cancer Institute and UCL Hospitals, Gynecological Oncology, United Kingdom, London, United Kingdom, 4Princess Margaret Cancer Centre, Toronto, ON, Canada, 5Centre Leon Berard, Lyon, France, 6Cabrini Hospital, Malvern, VIC, Australia, 7Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni (Ospedale Bellinzona e Valli), Bellinzona, Switzerland, 8National Cancer Center Hospital, Tokyo, Japan, 9The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom, 10Gustave Roussy Cancer Campus, Villejuif, France, 11British Columbia Cancer Agency, Vancouver, BC, Canada, 12Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, 13Poznan University of Medical Sciences, Poznan, Poland, 14National Cancer Center Korea, Goyang-si, South Korea, 15Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA, 16Pfizer Oncology, Cambridge, MA, USA, 17Pfizer Oncology, San Diego, CA, USA, 18Pfizer, Inc., Groton, CT, USA, 19Arizona Oncology (US Oncology Network), Phoenix, AZ, USA
• LBA#2: Worry and regret in the prospective multi-centre TUBA study in BRCA1/2 mutation carriers M.P.Steenbeek, M.G.Harmsen, D.TUBA group, R.P.M.G.Hermens and J.A.de Hullu
  Radboud University Medical Center, Nijmegen, Netherlands
• LBA#3: WISP: A prospective, multi-center trial of salpingectomy with delayed oophorectomy versus risk reducing salpingo-oophorectomy in women at increased risk for hereditary ovarian cancer
  K.H.Lu1, D.R.Nebgen1, B.Norquist2, D.J.Bowen2, J.N.Bakkum-Gamez3, I.Romero4, K.Long Roche5, D.A.Levine6, B.Soletsky1, J.Carter5, M.Hickey7, J.Crase1, K.Gavin8, D.Polinsky1 and E.M.Swisher2
  1The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2University of Washington Medical Center, Seattle, WA, USA, 3Mayo Clinic, Rochester, MN, USA, 4The University of Chicago Medicine, Chicago, IL, USA, 5Memorial Sloan Kettering Cancer Center, New York, NY, USA, 6NYU Langone Health, New York, NY, USA, 7University of Melbourne, Melbourne, Australia, 8University of Minnesota Cancer Center, Minneapolis, MN, USA
• LBA#4: A phase II trial of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
  E.Zsiros, P.J.Frederick, S.N.Akers, K.Attwood, K.Wang, S.B.Lele and K.Odunsi
  Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
• LBA#5: Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer
  F.J.Backes, L.Wei, D.E.Cohn, R.Salani, J.L.Hays, J.M.Fowler, L.J.Copeland and D.M.O’Malley
  The Ohio State University, James Cancer Hospital, Columbus, OH, USA